Xenon Pharmaceuticals Inc.
XENE
$37.11
-$0.40-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.24% | -35.71% | -46.81% | -29.57% | -22.05% |
| Total Depreciation and Amortization | -1.40% | 12.46% | 200.64% | -61.42% | 6.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.41% | 110.07% | -17.08% | 510.43% | 142.14% |
| Change in Net Operating Assets | -73.22% | -104.98% | 958.04% | 72.38% | 42.14% |
| Cash from Operations | -106.19% | -33.48% | -53.63% | -6.38% | 6.23% |
| Capital Expenditure | 89.63% | 77.13% | -903.85% | 50.83% | 29.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.55% | 180.35% | 141.42% | -95.33% | 268.59% |
| Cash from Investing | -24.66% | 179.90% | 141.08% | -96.33% | 291.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -96.26% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -96.26% | -- | -- |
| Foreign Exchange rate Adjustments | 412.87% | 82.56% | -570.33% | 118.75% | -156.27% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.94% | 70.97% | 12.27% | -240.23% | 1,669.31% |